Skip to content
OpenCapital
Get started

Mineralys Therapeutics, Inc. MLYS Held-to-Maturity Debt Securities - Fair Value

Held-to-Maturity Debt Securities - Fair Value at other companies

Wells Fargo & Company logo
Wells Fargo & CompanyWFC
$171.3B-9.6%
BK
BKBK
$45.94B+2.9%
State Street logo
State StreetSTT
$24.38B-39.7%
PNC Financial Services logo
PNC Financial ServicesPNC
$69.47B-2.1%
Bank of America logo
Bank of AmericaBAC
$433.61B-4.6%
Wells Fargo & Company logo
Wells Fargo & CompanyWFC
$204.17B-10.2%

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K—
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.27B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:HeldToMaturitySecuritiesFairValue.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s held-to-maturity debt securities - fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s held-to-maturity debt securities - fair value?
Mineralys Therapeutics, Inc. (MLYS) reported held-to-maturity debt securities - fair value of $493.84M in Q4 2025.
How has Mineralys Therapeutics, Inc.'s held-to-maturity debt securities - fair value changed year-over-year?
Mineralys Therapeutics, Inc.'s held-to-maturity debt securities - fair value increased by 333.4% year-over-year, from $113.95M to $493.84M.
What is the long-term trend for Mineralys Therapeutics, Inc.'s held-to-maturity debt securities - fair value?
Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s held-to-maturity debt securities - fair value has grown at a 180.5% compound annual growth rate (CAGR), from $22.39M to $493.84M.